SCHEMBL29270852

SCHEMBL29270852

CCc1noc(-c2ccc3c(c2)N(Cc2ccc(Cl)cc2)C(=O)[C@@H](CC(C)(C)NC(=O)O)CS3)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 2/20 0.37
▸ PTGDR Q13258 1/20 0.37
▸ TP53 P04637 3/20 0.35
▸ MAPT P10636 4/20 0.34
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ERCC1 P07992 1/20 0.34
▸ ERCC4 Q92889 1/20 0.34
▸ S1PR4 O95977 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ S1PR5 Q9H228 1/20 0.33
▸ PPARG P37231 2/20 0.33
▸ PPARA Q07869 2/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29270819 0.84 NOTUM (0.37) TP53MAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL26961675 0.81 XIAP (0.37) PTGDR2PTGDRTP53MAPTLMNA
SCHEMBL29270847 0.80 TP53 (0.47) TP53MAPTLMNASMN1; SMN2NPC1
SCHEMBL29270690 0.80 ALDH1A1 (0.41) TP53MAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL29270844 0.78 CNR2 (0.32) —
SCHEMBL29270781 0.78 TP53 (0.37) PTGDR2TP53MAPTLMNASMN1; SMN2
SCHEMBL29270756 0.78 HCRTR1 (0.32) —
SCHEMBL29270780 0.77 SHMT1 (0.31) TP53
SCHEMBL29270810 0.77 TP53 (0.35) TP53MAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL29270805 0.77 CNR2 (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116964048-A Bicyclic tetrahydroazepine derivatives for the treatment of cancer 豪夫迈·罗氏有限公司 2023-10-27 — — CN disclosed
Send feedback